SCHEMBL2895355

SCHEMBL2895355

Cc1cc(C(C)N2C(=O)c3ccccc3C2=O)c(Cl)nn1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.42
TSHR P16473 1/20 0.42
MAOB P27338 1/20 0.42
LMNA P02545 2/20 0.40
ALDH1A1 P00352 3/20 0.39
HTT P42858 2/20 0.39
TDP1 Q9NUW8 1/20 0.38
NPSR1 Q6W5P4 2/20 0.37
HPGD P15428 1/20 0.37
NPY1R P25929 1/20 0.37
NPY2R P49146 1/20 0.37
TP53 P04637 2/20 0.36
MAPK1 P28482 1/20 0.35
ALOX15 P16050 1/20 0.35
KMT2A Q03164 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2896546 0.87 LMNA (0.41) USP2TSHRLMNAALDH1A1HTT
SCHEMBL21362090 0.84 LMNA (0.42) USP2TSHRLMNAALDH1A1HTT
SCHEMBL2894014 0.79 LMNA (0.42) USP2TSHRLMNAALDH1A1HTT
SCHEMBL478794 0.79 TDP1 (0.48) TSHRMAOBALDH1A1TDP1KMT2A
SCHEMBL14870378 0.79 EGFR (0.42) USP2TSHRLMNAALDH1A1TDP1
SCHEMBL17718345 0.79 EGFR (0.42) USP2TSHRLMNAALDH1A1TDP1
SCHEMBL251676 0.77 HPGD (0.38) USP2TSHRLMNAALDH1A1HTT
SCHEMBL20072553 0.77 HTT (0.38) USP2TSHRLMNAALDH1A1HTT
SCHEMBL251675 0.77 HPGD (0.38) USP2TSHRLMNAALDH1A1HTT
SCHEMBL21362091 0.76 USP2 (0.41) USP2TSHRLMNAALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440666-B2 Pyridazinone compounds and P2X7 receptor inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-05-14 US disclosed
US-8440666-B2 Pyridazinone compounds and P2X7 receptor inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-05-14 US disclosed
US-8440666-B2 Pyridazinone compounds and P2X7 receptor inhibitors NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-05-14 US disclosed
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS NISSAN CHEMICAL INDUSTRIES LIMITED 2010-11-11 US disclosed
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS NISSAN CHEMICAL INDUSTRIES LIMITED 2010-11-11 US disclosed
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS NISSAN CHEMICAL INDUSTRIES LIMITED 2010-11-11 US disclosed
WO-2009057827-A1 PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS P2RY1, P2RX7, P2RX1 USP2 4656/4885TSHR 989/4885MAOB 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.